Skip to main content
. Author manuscript; available in PMC: 2020 Sep 1.
Published in final edited form as: Free Radic Biol Med. 2019 Jul 3;141:322–337. doi: 10.1016/j.freeradbiomed.2019.07.001

Fig. 2.

Fig. 2

Effect of intranasal administration of rh-Ghrelin on brain infarct area (A-B), short-term neurological function (C) and body weight (D) at 48 h post HI. (A-B) TTC staining showed that medium (0.04μg/kg) and high (0.12μg/kg) doses of rh-Ghrelin treatment significantly reduced infarct area when compared with vehicle. (C) Geotaxis test showed reflex time increased significantly after HI when compared with sham group. All three doses of rh-Ghrelin decreased the reflex time significantly compared with the Vehicle group, and the medium dose group (0.12 μg/kg) showed the shortest time in the three doses groups. (D) Animals in vehicle group showed to lose significant weight compared with sham and all three treatment groups after HI. *P < 0.05 vs. sham; #P < 0.05 vs. vehicle; @P < 0.05 vs. HI+ rh-Ghrelin (0.02 μg/kg). Data are represented as mean ± SD, n= 6 for each group.

HHS Vulnerability Disclosure